Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma

[1]  C. Marosi,et al.  Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours , 2020, ESMO Open.

[2]  M. Tiseo,et al.  Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. , 2020, Lung cancer.

[3]  M. Weller,et al.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.

[4]  A. Mansfield,et al.  ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance , 2020, Oncoimmunology.

[5]  C. Marosi,et al.  Association of systemic inflammation with local tumour characteristics and survival in glioma patients , 2019, Annals of Oncology.

[6]  C. Marosi,et al.  OS1.1 Plasma PD-L1 levels over time differ between glioblastoma and lower-grade glioma patients , 2019, Neuro-Oncology.

[7]  M. Weller,et al.  How we treat glioblastoma , 2019, ESMO Open.

[8]  Y. Toiyama,et al.  Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression , 2019, Annals of Surgical Oncology.

[9]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[10]  D. Olive,et al.  Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma , 2019, Oncoimmunology.

[11]  M. Weller,et al.  Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate , 2018, Nature Medicine.

[12]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[13]  Timothy R. Smith,et al.  Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. , 2018 .

[14]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[15]  C. Marosi,et al.  Correlation of immune phenotype with IDH mutation in diffuse glioma , 2017, Neuro-oncology.

[16]  G. Reifenberger,et al.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[17]  A. Giobbie-Hurder,et al.  Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade , 2017, Cancer Immunology Research.

[18]  A. Brandes,et al.  OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 , 2017 .

[19]  Ken‐ichiro Yoshida,et al.  Higher preoperative serum levels of PD‐L1 and B7‐H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF‐targeted therapy and unfavorable prognosis of renal cell carcinoma , 2016, Cancer medicine.

[20]  F. Greten,et al.  High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. , 2016, European journal of cancer.

[21]  Qingchang Li,et al.  Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma , 2015, BMC Cancer.

[22]  Yong Wang,et al.  Diagnostic and prognostic value of a disintegrin and metalloproteinase-17 in patients with gliomas , 2014, Oncology letters.

[23]  D. Amelio,et al.  Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  H. Zentgraf,et al.  Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.

[25]  S. Lange,et al.  Adjusting for multiple testing--when and how? , 2001, Journal of clinical epidemiology.

[26]  R. Jain,et al.  During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium , 1996, Nature Medicine.

[27]  T. Strojnik,et al.  Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. , 2014, Anticancer research.

[28]  R. Jain,et al.  During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. , 1996, Nature medicine.